AstraZeneca (AZN) faces mixed pivotal evidence for gastric-cancer ADC sone-ve
An overall-survival benefit is accompanied by a missed centrally assessed progression endpoint.
Get analysis like this in your inbox.
Join investors and analysts following Lex Commentary.
AstraZeneca's sonesitatug vedotin produced a survival benefit in a Phase 3 study of previously treated CLDN18.2-positive gastro-oesophageal cancer, but missed its other primary endpoint. Median overall survival in the overall population was 10.6 months with the antibody-drug conjugate, compared with 6.4 months in the control group.
Blinded independent central review found median progression-free survival of 4.2 months versus 3.8 months, failing the trial's specified test. Investigator-assessed progression results were more favourable, but cannot simply replace the prespecified central assessment.
The divergence creates a more complicated regulatory discussion than an unqualified pivotal-trial win. Overall survival is clinically important; the complete statistical plan and consistency of the evidence also matter.
AstraZeneca maintains that the dataset can support regulatory discussions. Investors should distinguish that assessment from an agreed approval pathway. The commercial opportunity depends on how authorities interpret the totality of evidence and which patient population, if any, they consider sufficiently supported.
Source: Fierce Biotech reporting, 25 October.